EFR3A

Across TCGA pan-cancer cohorts, EFR3A RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of EFR3A’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where EFR3A RNA is more highly expressed in tumor relative to normal tissue. In most cancer types EFR3A is over-expressed in tumor, although a few such as UCEC show the opposite, repressed pattern.

HNSC, LIHC, and BRCA are the cancer types where EFR3A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in EFR3A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	All	+1.077	<.001	11	view →
LIHC	Male	II,III,IV	+1.265	<.001	7	view →
BRCA	All	II,III,IV	+0.762	<.001	6	view →
LUAD	All	All	+0.302	.001	4	view →
CHOL	All	All	+0.916	.009	2	view →
UCEC	All	All	−0.885	<.001	2	view →
KIRC	All	All	+0.185	.027	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

EFR3A–HNSC

Open the HNSC breakdown →